Nifedipine Tablet, Extended Release
Product Images NDC 0615-8549

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 0615-8549). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

01 (Nifedipine 8549 1)

FDA Label Image

02 (Nifedipine 8549 2)

02 (Nifedipine   8549 2)
This text provides a list of adverse effects reported for Nifedipine extended-release tablets and placebo. The adverse effects include headache, fatigue, dizziness, constipation, and nausea, accompanied by their respective percentages based on a sample size of 707 individuals for Nifedipine and 266 individuals for placebo. This data highlights the frequency of these adverse effects for each treatment option.*
FDA Label Image

03 (Nifedipine 8549 3)

03 (Nifedipine   8549 3)
This data table compares the adverse effects of Nifedipine capsules with a placebo. The table lists the percentage of patients experiencing various side effects such as dizziness, lightheadedness, flushing, headaches, weakness, nausea, muscle cramps, and more for each group of patients (N=226 for Nifedipine and N=235 for Placebo). It provides a useful breakdown of the different adverse effects and their prevalence in the two groups.*
FDA Label Image

04 (Nifedipine 8549 4)

FDA Label Image

Principal Display Panel (Nifedipine 8549 5)

Principal Display Panel (Nifedipine   8549 5)
This text provides detailed information about Nifedipine Extended-Release Tablets, USP 60 mg, including lot numbers, packaging details, manufacturing information, storage instructions, dosage guidelines, and the presence of a trademark. It emphasizes swallowing the tablets whole and not dividing them. The text also mentions that the product is for institutional use only and lists the tablet composition.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.